Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia

Frontiers in Behavioral Neuroscience

Volumn , Issue OCT, 2013, Pages

  Sumiyoshi, Tomiki ^a   Higuchi, Yuko ^b   Uehara, Takashi ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

5 HT receptors; Atypical antipsychotics; Cognitive function; Electrophysiology; Energy metabolism; Lactate; Neuropsychology; Second generation

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; CLOZAPINE; LURASIDONE; MELPERONE; OLANZAPINE; PEROSPIRONE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; TANDOSPIRONE;

ARTICLE; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; COGNITION; COGNITIVE DEFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENERGY METABOLISM; EVENT RELATED POTENTIAL; EXPERIMENTAL RAT; HUMAN; LACTIC ACIDOSIS; NERVE CELL NETWORK; NEUROIMAGING; NONHUMAN; PREFRONTAL CORTEX; QUALITY OF LIFE; RECEPTOR UPREGULATION; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; VERBAL MEMORY;

EID: 84886286165     PISSN: 16625153     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnbeh.2013.00140     Document Type: Article

References (40)

1. Araki, T., Yamasue, H., Sumiyoshi, T., Kuwabara, H., Suga, M., Iwanami, A., et al. (2006). Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog. Neuropsy-chopharmacol. Biol. Psychiatry 30, 204-208. doi:10.1016/j.pnpbp.2005. 10.015
2. Bortolozzi, A., Masana, M., Diaz- Mataix, L., Cortes, R., Scorza, M. C., Gingrich, J. A., et al. (2010). Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors. Int. J. Neuropsychopharmacol. 13, 1299-1314. doi:10.1017/S146114571000009X
3. Diaz-Mataix, L., Scorza, M. C., Bor-tolozzi, A., Toth, M., Celada, P., and Artigas, F. (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25, 10831-10843. doi:10.1523/JNEUROSCI.2999-05. 2005
4. Goldberg, T. E., Goldman, R. S., Bur-dick, K. E., Malhotra, A. K., Lencz, T., Patel, R. C., et al. (2007). Cognitive improvement after treatment with second-generation antipsy-chotic medications in first-episode schizophrenia: is it a practice effect? Arch. Gen. Psychiatry 64, 1115-1122. doi:10.1001/archpsyc. 64.10.1115
5. Gronier, B. (2008). Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptors agonists: an electrophysio-logical study in the rat. Neuroscience 156, 995-1004. doi:10.1016/j. neuroscience.2008.08.033
6. Harvey, P. D., Ogasa, M., Cucchiaro, J., Loebel, A., and Keefe, R. S. (2011). Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 127, 188-194. doi:10. 1016/j.schres.2011.01.004
7. Harvey, P. D., Siu, C. O., Hsu, J., Cucchiaro, J., Maruff, P., and Loebel, A. (2013). Effect of lurasi-done on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur. Neuropsychopharmacol. doi:10. 1016/j.euroneuro.2013.08.003
8. Heinrichs, D.W., Hanlon, T.E., and Carpenter, W. T. J. (1984). The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 10, 388-398. doi:10.1093/schbul/10.3.388
9. Higuchi, Y., Sumiyoshi, T., Ito, T., and Suzuki, M. (2013). Perospirone normalized P300 and cognitive function in a case of early psychosis. J. Clin. Psychopharmacol. 33, 263-266. doi:10.1097/JCP.0b013e318287c527
10. Higuchi, Y., Sumiyoshi, T., Kawasaki, Y., Ito, T., Seo, T., and Suzuki, M. (2010). Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report. J. Clin. Psychopharma-col. 30, 732-734. doi:10.1097/JCP. 0b013e3181faa57d
11. Higuchi, Y., Sumiyoshi, T., Kawasaki, Y., Matsui, M., Arai, H., and Kurachi, M. (2008). Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia:aLORETA analysis of P300. Schizophr. Res. 101, 320-330. doi:10.1016/j.schres.2008.01.020
12. Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., and Hajos, M. (2008). Neurophysiological bio-markers for drug development in schizophrenia. Nat. Rev. Drug Dis-cov. 7, 68-83. doi:10.1038/nrd2463
13. Keefe, R. S., Bilder, R. M., Davis, S. M., Harvey, P. D., Palmer, B. W., Gold, J. M., et al. (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64, 633-647. doi:10.1001/ archpsyc.64.6.633
14. Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., and Celada, P. (2011). 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb. Cortex 22, 1487-1497. doi:10.1093/ cercor/bhr220
15. Maruff, P., Thomas, E., Cysique, L., Brew, B., Collie, A., Snyder, P., et al. (2009). Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch. Clin. Neuropsychol. 24, 165-178. doi:10.1093/arclin/ acp010
16. Meltzer, H.Y.(1991).The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17, 263-287. doi:10. 1093/schbul/17.2.263
17. Meltzer, H. Y. (2002). Action of atypical antipsychotics. Am. J. Psychiatry 159, 153-154. doi:10.1176/appi.ajp. 159.1.153-a
18. Meltzer, H. Y., Matsubara, S., and Lee, J. C. (1989). Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238-246.
19. Norman, G. R., Sloan, J. A., and Wyr-wich, K. W. (2003). Interpretation of changes in health-related quality of life. Med. Care 41, 582-592. doi:10.1097/00005650-200305000-00004
20. Stockmeier, C. A., Dicarlo, J. J., Zhang, Y., Thompson, P., and Meltzer, H. Y. (1993). Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 266, 1374-1384.
21. Sumiyoshi, C., and Sumiyoshi, T. (in press). Functional outcome in patients with schizophrenia: the concept and the measurement. Act Nerv. Super.
22. Sumiyoshi, T. (2008). A possible dose-side effect relationship of antipsy-chotic drugs: Relevance to cognitive function in schizophrenia. Expert. Rev. Clin. Pharmacol. 1, 791-802. doi:10.1586/17512433.1.6.791
23. Sumiyoshi, T. (2012). Serotonin 1A receptors in the action of antipsy-chotic drugs. J. Psychopharma-col. 26, 1283-1284. doi:10.1177/ 0269881112449398
24. Sumiyoshi, T. (2013). Antipsychotic treatments; Focus on lurasidone. Front. Psychopharmacol. 26:102. doi: 10.3389/fphar.2013.00102
25. Sumiyoshi, T. (in press). Serotonin 5-HT1Areceptorsintheactionof arip-iprazole. J. Clin. Psychopharmacol.
26. Sumiyoshi, T., Bubenikova-Valesova, V., Horacek, J., and Bert, B. (2008). Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv. Ther. 25, 1037-1056. doi:10.1007/s12325-008-0102-2
27. Sumiyoshi, T., and Higuchi, Y. (2013). Facilitative effect of serotonin1A receptor agonists on cognition in patients with schizophrenia. Curr. Med. Chem. 20, 357-362. doi:10. 2174/092986713804870846
28. Sumiyoshi, T., Higuchi, Y., Itoh, T., and Kawasaki, Y. (2011). "Electrophysio-logical imaging evaluation of schizophrenia and treatment response," in Handbook of Schizophrenia Spectrum Disorders, ed. M. S. Risner (New York: Springer).
29. Sumiyoshi, T., Higuchi, Y., Itoh, T., Matsui, M., Arai, H., Suzuki, M., et al. (2009). Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res. 172, 180-183. doi:10.1016/j.pscychresns. 2008.07.005
30. Sumiyoshi, T., Higuchi, Y., Kawasaki, Y., Matsui, M., Kato, K., Yuuki, H., et al. (2006). Electrical brain activity and response to olanzap-ine in schizophrenia: a study with LORETA images of P300. Prog. Neu-ropsychopharmacol. Biol. Psychiatry 30, 1299-1303. doi:10.1016/j.pnpbp. 2006.04.028
31. Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., et al. (2001a). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neurolep-tic treatment. Am. J. Psychiatry 158, 1722-1725. doi:10.1176/appi. ajp.158.10.1722
32. Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Kurachi, M., Uehara, T., et al. (2001b). The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol. Psychiatry 49, 861-868. doi:10.1016/S0006-3223(00)01025-8
33. Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertugrul, A., and Meltzer, H. Y. (2007). Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95, 158-168. doi:10.1016/j.schres.2007. 06.008
34. Sumiyoshi, T., Stockmeier, C. A., Overholser, J. C., Dilley, G. E., and Meltzer, H. Y. (1996). Serotonin1A receptors are increased in post mortem prefrontal cortex in schizophrenia. Brain Res. 708, 209-214 doi:10.1016/0006-8993(95)01361-X
35. Sumiyoshi, T., Suzuki, K., Sakamoto, H., Yamaguchi, N., Mori, H., Shiba, K., et al. (1995). Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology 12, 57-64. doi:10.1038/sj.npp. 1380239
36. Uehara, T., Itoh, H., Matsuoka, T., Rujescu, D., Genius, J., Seo, T., et al. (2012). Effect of transient blockade of N-methyl-d-aspartate receptors at neonatal stage on stress-induced lactate metabolism in the medial prefrontal cortex of adult rats: role of 5-HT1A receptor ago-nism. Synapse 66, 408-417. doi:10. 1002/syn.21529
37. Uehara, T., and Sumiyoshi, T. (2013). "Lactate metabolism as a new target for the therapeutics of schizophrenia," in Frontiers in Clinical Drug Research-CNS and Neurological Disorders, ed. A. U. Rahman (Sharjah: Bentham Science Publishers).
38. Uehara, T., Sumiyoshi, T., Itoh, H., and Kurata, K. (2008). Lactate production and neurotransmitters; evidence from microdialysis studies. Pharmacol. Biochem. Behav. 90, 273-281. doi:10.1016/j.pbb.2008.04. 001
39. Woodward, N.D., Purdon, S.E., Meltzer, H. Y., and Zald, D. H. (2005). A meta-analysis of neuropsychologi-cal change to clozapine, olanza-pine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsy-chopharmacol. 8, 457-472. doi:10. 1017/S146114570500516X
40. Wyss, M. T., Jolivet, R., Buck, A., Mag-istretti, P. J., and Weber, B. (2011). In vivo evidence for lactate as a neuronal energy source. J. Neu-rosci. 31, 7477-7485. doi:10.1523/ JNEUROSCI.0415-11.2011